Another limitation is that only a small subset of patients with breast cancer underwent Trop2-targeted ADC therapy, which restricted our ability to evaluate the effectiveness of 68Ga-MY6349 PET/CT in predicting the clinical outcomes of Trop2-targeted ADC treatment. The gene discussed is TACSTD2; the disease is breast cancer.